))
5 Surprising Causes of Life Science Deal Failures
Manage episode 416232597 series 3506216
Darshan Kulkarni에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Darshan Kulkarni 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
We discuss the five common reasons behind the failure of mergers, acquisitions and licensing deals in the life sciences industry.
Inadequate understanding of capability, where focusing solely on financials without comprehending the target company's regulatory and compliance processes leads to failure.
The side project dilemma, illustrated by Philip Morris' venture into pharmaceuticals, emphasizing the importance of aligning with core business objectives.
Clash of perspectives, exemplified by cultural and business differences between BioGene and Novartis, highlighting the necessity of alignment in strategic vision.
Low margins on generic drugs, as seen in Teva's acquisition of Actavis, revealing the
challenge of profitability in this sector.
Overpaying, stressing the significance of thorough due diligence to avoid paying more than a company's actual value.
For assistance with M&A due diligence, contact us at 302-252-6959.
Support the show
109 에피소드
공유
